GlobeNewswire Press

  1. Sandoz Announces Plans To Build New Technical Development Center In Slovenia 7/20/2023

    Sandoz, a global leader in generic and biosimilar medicines, today announced an investment of approximately USD 90 million at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma Development Center by 2026.

  2. Prokidney Announces Plans For New Cell Therapy Manufacturing Facility In North Carolina 6/13/2023

    ProKidney Corp. (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on preserving kidney function in patients suffering from chronic kidney disease (CKD), today announced its agreement to purchase a 210,000 square foot facility and approximately 22 acres of land in Greensboro, N.C., to support the Company’s future commercial manufacturing needs for REACT®, its proprietary REnal Autologous Cell Therapy, currently in Phase 3 development for the treatment of diabetic CKD.

  3. Eyepoint Pharmaceuticals Announces Plans To Build New Manufacturing Facility In Massachusetts 1/23/2023

    EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders, today announced that it has entered into a lease agreement to design and construct a 40,000-square-foot manufacturing facility in Northbridge, Massachusetts to support the global manufacturing of programs, including EYP-1901 and YUTIQ.

  4. MaxCyte Debuts New State-Of-The-Art Headquarters In Maryland's I-270 Biotech Corridor 9/21/2022

    MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research, as well as next-generation cell therapeutic discovery, development and commercialization, today announced that it has relocated its headquarters to 9713 Key West Avenue in Rockville, Maryland, 20850, within Maryland’s I-270 Biotech Corridor.

  5. CDMO AGC Biologics Invests In New Viral Vector Suspension Capabilities In Colorado 5/17/2022

    AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it is adding viral vector suspension technology and capacity for the development and manufacturing of gene therapies at its commercial-grade campus in Longmont, Col., USA.

  6. CDMO FUJIFILM Diosynth Biotechnologies Breaks Ground On Expansion Of New BioProcess Innovation Center In North Carolina 4/26/2022

    FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) with expertise in the development and manufacture of recombinant biopharmaceuticals and viral gene therapies, held a groundbreaking ceremony for the expansion of its BioProcess Innovation Center in Research Triangle Park (RTP) on April 21, 2022.

  7. CDMO Berkshire Sterile Manufacturing Adds New IMA Lyophilizer To Increase Development Capabilities 4/7/2022

    Berkshire Sterile Manufacturing (BSM) purchased a new IMA lab-scale lyophilizer to support their lyophilization development studies – a service that was added in Q1 2022. This acquisition is the company’s fourth lyophilizer, and second lab-scale model.

  8. Intellia Therapeutics Enters Lease Agreement To Build Manufacturing Facility For Its CRISPR-Based Therapies 2/23/2022

    Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, today announced that it has entered into a lease agreement to develop a 140,000-square-foot manufacturing facility in Waltham, Massachusetts, to support the manufacturing of key components for its CRISPR-based investigational therapies.

  9. POMS Corporation Releases New MES Dashboards & Batch Records For Drug Manufacturers 1/4/2022

    POMS Corporation releases POMSnet Falcon 2021.2 MES Dashboard and Analytics. POMSnet Falcon is perched to become the GMP facility standard for dashboards, reports, & analytics.

  10. MasterControl Announces Annual Recurring Revenue Milestone 11/18/2021

    MasterControl, a global provider of software solutions for life sciences and other regulated industries, today announced it has reached $100 million in annual recurring revenue (ARR), led by their signature software solutions, Quality Excellence and Manufacturing Excellence, as well as the recent launch of MasterControl Insights.